SERIES 7 | FINANCIAL REGULATION COURSES
FINRA Rule 2114 — Recommendations to Customers in OTC Equity Securities — prohibits any FINRA member firm or associated person from recommending that a customer purchase or sell short any OTC equity security unless the member has first reviewed the current financial statements of the issuer, reviewed current material business information about the issuer, and made a determination that such information provides a reasonable basis under the circumstances for making the recommendation — establishing a mandatory pre-recommendation due diligence framework specifically designed to protect retail investors in the over-the-counter equity markets where the absence of exchange listing standards, minimal disclosure requirements, and thin trading liquidity create dramatically elevated risks of fraud, manipulation, and uninformed investment decision-making compared to the exchange-listed equity markets.
Rule 2114 was adopted from its predecessor NASD Rule 2315 — effective June 15, 2009 in the Consolidated FINRA Rulebook — and was most recently amended effective December 5, 2011. It reflects a fundamental regulatory insight that the OTC equity markets — encompassing the OTCQX, OTCQB, and OTC Pink tiers operated by OTC Markets Group, as well as other over-the-counter trading venues — host a significant population of issuers about whom reliable, current financial information may be difficult to obtain, inconsistent in quality, or deliberately obscured by promoters and insiders engaged in pump-and-dump schemes and other manipulative strategies.
The rule's preliminary note is explicit and important — the requirements of Rule 2114 are in addition to other existing member obligations including the suitability obligations of FINRA Rule 2111 and Regulation Best Interest. Rule 2114 is not a substitute for suitability analysis — it is an additional layer of due diligence that must be completed before suitability can even be properly assessed. And critically the note confirms that the rule is not intended to act as a presumption or safe harbour — satisfying Rule 2114's review requirements does not automatically mean the recommendation is suitable or otherwise appropriate.
What Is an OTC Equity Security — The Scope of the Rule
Rule 2114 applies specifically to OTC equity securities — defined by reference to FINRA Rule 6420 as any equity security that is not listed on a national securities exchange and that is not otherwise excluded from the definition. The OTC equity universe encompasses the full range of non-exchange-listed stocks including those traded on OTC Markets Group's three-tiered system — OTCQX Best Market, OTCQB Venture Market, and OTC Pink — as well as stocks that trade over the counter through the OTC Bulletin Board and other venues.
The market structure of OTC equity trading differs fundamentally from exchange-listed equity trading in ways that make Rule 2114's pre-recommendation due diligence requirement essential. Exchange-listed companies must meet and continuously maintain quantitative and qualitative listing standards — including minimum share price, minimum market capitalisation, minimum shareholder equity, and corporate governance requirements — that provide a baseline assurance of viability and transparency. OTC equity issuers face no equivalent listing standards — any entity that can attract market maker interest and meet the minimal requirements for OTC quotation can have its securities quoted in the OTC markets regardless of financial condition, business viability, or disclosure quality.
This structural difference makes the OTC equity market a fertile environment for securities fraud — particularly microcap fraud schemes in which promoters accumulate shares of thinly traded OTC companies, generate artificial buying interest through misleading promotional campaigns conducted through social media, email blasts, and other channels, and then sell their accumulated shares into the promotional buying pressure at inflated prices — leaving retail investors who purchased at the top with significant losses when the promotion ends and the price collapses.
FINRA's 2025 Annual Regulatory Oversight Report reaffirmed that microcap manipulation remains a top examination priority with particular focus on broker-dealer gatekeeper obligations — the expectation that member firms serving as the gatekeepers to the OTC equity markets will not facilitate manipulative schemes by recommending OTC securities without conducting the due diligence that Rule 2114 requires.
The Review Requirement — What Must Be Examined
Rule 2114(a) establishes the mandatory pre-recommendation review requirement — before recommending any OTC equity security to any customer the member must review two specific categories of information and make a reasonable basis determination based on that review.
The first category is current financial statements — precisely defined in Rule 2114(b)(1) to ensure that the financial information reviewed is genuinely current and reflects the issuer's present financial condition rather than outdated information that may no longer accurately describe the company's situation.
For domestic issuers — issuers that are not foreign private issuers — current financial statements under Rule 2114 include a balance sheet dated less than fifteen months before the recommendation date, a statement of profit and loss for the twelve months preceding the balance sheet date, and if the balance sheet is more than six months old additional statements of profit and loss covering the period from the balance sheet date to a date less than six months before the recommendation. The rule also requires review of all publicly available financial statements filed with the SEC or other regulatory authorities during the twelve months preceding the recommendation — including any registration statements or Regulation A filings containing financial information.
For foreign private issuers — non-US companies that file with the SEC under the foreign private issuer framework — the currency requirements are slightly relaxed. The balance sheet must be dated less than eighteen months before the recommendation — rather than fifteen months — and additional profit and loss statements are required if the balance sheet is more than nine months old rather than six months.
The fifteen-month and eighteen-month balance sheet currency requirements are deliberately specific — they establish clear minimum standards for what counts as current financial information while providing enough flexibility to accommodate the different filing cycles and reporting timelines of different categories of issuers. A balance sheet that is sixteen months old does not satisfy the Rule 2114 definition of current financial statements for a domestic issuer — no matter how detailed or otherwise informative it might be.
The second category is current material business information — defined in Rule 2114(b)(2) as information that is ascertainable through the reasonable exercise of professional diligence and that a reasonable person would take into account in reaching an investment decision. This broader and more qualitative standard encompasses the full range of non-financial information relevant to an investment decision — recent press releases, regulatory filings, material contract announcements, management changes, litigation developments, product launches, and any other information that could materially affect the issuer's value or investment prospects.
The ascertainable through reasonable exercise of professional diligence standard is important — the member must actually look for and find current material business information through a diligent search, not merely note its absence. A member who makes no effort to find current business information about an OTC issuer has not satisfied this requirement regardless of whether such information exists.
The Determination — Reasonable Basis Under the Circumstances
After reviewing the required financial statements and current material business information the member must make a determination that the reviewed information provides a reasonable basis under the circumstances for making the recommendation.
This determination is a substantive professional judgment — not a box-checking exercise. A member who reviews financial statements showing that an OTC issuer has no revenue, no assets, and rapidly deteriorating cash reserves, and then recommends the security anyway, has not made a reasonable basis determination simply by having conducted the required review. The information reviewed must actually support a reasonable basis for the recommendation — financial statements that reveal a financially distressed or fundamentally unsound company support the opposite conclusion.
The circumstances qualifier — a reasonable basis under the circumstances — acknowledges that different OTC issuers present different informational environments. A development-stage company with no revenue may legitimately be the subject of a reasonable basis recommendation if its financial statements and business information support a compelling investment thesis about future value — while a company with revenues, established operations, and readily available financial information that nonetheless recommends on the basis of incomplete or outdated information has failed the determination requirement more clearly.
Compliance Requirements — Designated Reviewer and Documentation
Rule 2114(c) establishes the compliance infrastructure that member firms must implement to ensure the pre-recommendation review is conducted systematically and is appropriately supervised and documented.
Each member must designate a specific registered person to conduct the review required by the rule — and that designated person must either be registered as a General Securities Principal or General Securities Sales Supervisor, or must have their conduct in complying with Rule 2114 supervised by a General Securities Principal or General Securities Sales Supervisor. This supervision requirement ensures that the review function is subject to principal oversight and is not conducted in isolation by registered representatives without adequate compliance oversight.
The documentation requirement is equally specific — the member must document the information reviewed, the date of the review, and the name of the person performing the review. When the designated reviewer is not themselves a registered principal the documentation must also identify the General Securities Principal or General Securities Sales Supervisor who supervised the review. These documentation requirements create the evidentiary record that FINRA examiners will review to assess whether the pre-recommendation due diligence was actually conducted and was appropriately thorough.
The Delinquent Filer Additional Requirement
Rule 2114(d) imposes a heightened review obligation when an OTC issuer has failed to make current filings required by its principal financial or securities regulatory authority — a situation that is itself a significant red flag about the issuer's transparency and compliance culture.
When a member discovers that an OTC issuer is delinquent in its required regulatory filings the pre-recommendation review must include an inquiry into the circumstances concerning the failure to make current filings — specifically investigating why the required filings have not been made and what that failure reveals about the issuer's situation. Based on all the facts and circumstances the member must make a written determination that the recommendation is appropriate despite the filing delinquency.
The written determination requirement for delinquent filers is more demanding than the general documentation requirement — it must be a substantive written analysis demonstrating that the member has considered the implications of the filing delinquency and has determined on an informed basis that the recommendation remains appropriate. A boilerplate written statement that the recommendation is appropriate without addressing the specific circumstances of the filing delinquency does not satisfy this requirement.
The Exemptions — When Rule 2114 Does Not Apply
Rule 2114(e) provides five specific exemptions from the review requirement — identifying categories of transactions and counterparties where the investor protection rationale for the pre-recommendation review is diminished by other characteristics of the transaction or the parties involved.
The first exemption covers private placement transactions — specifically transactions meeting the requirements of SEC Rule 504 of Regulation D and transactions with an issuer not involving any public offering under Section 4(a)(2) of the Securities Act. Private placements conducted under these exemptions involve sophisticated investors and regulatory frameworks that provide alternative protections.
The second exemption covers institutional accounts as defined in FINRA Rule 4512(c), qualified institutional buyers under SEC Rule 144A, and qualified purchasers under Section 2(a)(51) of the Investment Company Act. Institutional investors, QIBs, and qualified purchasers have the sophistication and resources to conduct their own due diligence — the paternalistic pre-recommendation review requirement is unnecessary when the customer is capable of independently evaluating OTC equity investments.
The third exemption covers issuers with total assets of at least fifty million dollars and shareholder equity of at least ten million dollars as stated in the most recent audited current financial statements. Large and financially substantial OTC issuers present reduced fraud risk because their financial scale makes the most common manipulative schemes economically impractical.
The fourth exemption covers securities of banks as defined in Section 3(a)(6) of the Exchange Act and insurance companies subject to state or federal regulatory oversight. These entities are subject to comprehensive regulatory oversight by banking and insurance regulators that provides alternative assurance of financial soundness and disclosure quality.
The fifth exemption covers securities with a bid price of at least fifty dollars per share — or for unit securities a per-share equivalent of at least fifty dollars excluding warrants, options, and rights. The fifty-dollar bid price threshold serves as a proxy for the market's assessment of value and legitimacy — securities trading at fifty dollars or above are generally not the targets of the pump-and-dump schemes that Rule 2114's due diligence requirement is primarily designed to prevent.
Connection to the OTC Market Fraud Prevention Framework
Rule 2114 operates within a broader regulatory framework for preventing fraud and manipulation in the OTC equity markets — working alongside SEC Rule 15c2-11, which governs the publication of quotations for OTC securities and requires broker-dealers to review specified public information about an issuer before publishing quotations, and the anti-manipulation provisions of Section 10(b) of the Exchange Act and SEC Rule 10b-5.
The relationship between Rule 2114 and SEC Rule 15c2-11 is particularly important — Rule 15c2-11 governs the quotation of OTC securities while Rule 2114 governs recommendations to customers in those securities. A broker-dealer that publishes quotations in an OTC security in compliance with Rule 15c2-11 has not thereby satisfied Rule 2114's pre-recommendation review requirement — the two rules serve different purposes and impose independent obligations.
Examination Relevance and Key Takeaways
FINRA Rule 2114 is tested on the Series 7 examination in the context of OTC equity securities, pre-recommendation due diligence, current financial statements, and the five exemptions from the rule's requirements.
The key points to retain are these.
FINRA Rule 2114 — Recommendations to Customers in OTC Equity Securities — prohibits member firms and associated persons from recommending any OTC equity security — as defined in Rule 6420 — to any customer unless the member has first reviewed the issuer's current financial statements, reviewed current material business information, and determined that the information provides a reasonable basis for the recommendation. The rule's requirements are in addition to — not a substitute for — the suitability obligations of FINRA Rule 2111 and Regulation Best Interest.
Current financial statements for domestic issuers require a balance sheet less than fifteen months old, a profit and loss statement for the twelve preceding months, supplemental profit and loss statements if the balance sheet is more than six months old, and all publicly filed financial information from the preceding twelve months. For foreign private issuers the balance sheet currency requirement is eighteen months rather than fifteen months. Current material business information must be ascertainable through reasonable professional diligence and must be information a reasonable person would consider in making an investment decision. Members must designate a registered person — supervised by a General Securities Principal or General Securities Sales Supervisor — to conduct the review and must document the information reviewed, the review date, and the reviewer's identity. Delinquent filers require an additional written determination that the recommendation is appropriate despite the filing failure. Five exemptions apply — private placement transactions, institutional accounts and qualified investors, issuers with fifty million dollars in total assets and ten million dollars in shareholder equity, regulated banks and insurance companies, and securities with a bid price of fifty dollars or more per share.
